Navigation Links
FDA Panel Votes for Tougher Curbs on Vicodin, Other Painkillers
Date:1/27/2013

By Amanda Gardner
HealthDay Reporter

FRIDAY, Jan. 25 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel voted Friday to place tougher restrictions on prescription painkillers containing hydrocodone, potentially moving medications such as Vicodin into the same class as narcotics such as Oxycontin and Percocet.

Vicodin (hydrocodone plus acetaminophen) and other hydrocodone-containing drugs remain widespread targets for abuse, and the U.S. Drug Enforcement Administration has long requested that the FDA advisory panel undertake the review. The panel spent two days discussing the issue before voting on Friday afternoon, the Associated Press reported.

Currently, the medications are classified as Schedule III drugs but the DEA wants them placed within the more tightly controlled Schedule II designation, alongside painkillers such as Oxycontin and Percocet.

The FDA is not required to follow the recommendations of its advisory panels, but it typically does.

The issue has become a contentious one.

Supporters of a move to Schedule II status point to tragic deaths and suicides that have been the result of misuse of these prescription drugs.

But, opponents of that tougher classification fear that tightening access to the drugs would mean that people who really need them to ease pain will not be able to get them.

"This is really a decision of access versus diversion [for non-medical use]," explained Dr. Lynn Webster, president-elect of the American Academy of Pain Medicine, who said his organization was not necessarily in favor of or opposed to reclassification.

However, "it will have an impact on a lot of patients who have been receiving them for some time for legitimate purposes" if these drugs are reclassified, Webster added.

Dr. Andrew Kolodny, president of Physicians for Responsible Opioid Prescribing, called such concerns "completely bogus."

"Even if we change hydrocodone-containing products from Schedule III to Schedule II, it in no way jeopardizes access," he believes. "What this means is that patients who might be able to go to their doctor every six months would now have to see their doctor every three months [to get a prescription]."

Kolodny also contends that "people who are on long-term opioids are more likely to be harmed by that treatment than helped. There is very little difference between a heroin molecule and a hydrocodone molecule."

Few people seem to dispute the fact that too many of these opioid drugs are too widely available, even though the pharmaceutical industry has recently developed "abuse-resistant" formulations to help fight misuse.

Overall, some 22 million Americans have misused prescription painkillers of one kind or another since 2002, according to a report released earlier this month by the U.S. Substance Abuse and Mental Health Services Administration. The agency noted that prescription painkillers now rank only behind marijuana as a drug of abuse in the United States.

According to Webster, patients typically do not use two-thirds of the hydrocodone-containing medications they've been prescribed, meaning those leftover pills might become available for misuse.

"That suggests that there are way more drugs being prescribed than is necessary," Webster said. "And we know that basically 80 percent of all drugs used for non-medical purposes come from the medicine cabinet at home."

Added Kolodny, who is also chair of psychiatry at Maimonides Medical Center in New York City: "We have an epidemic of people with opioid addiction. That's what's really causing overdose deaths."

According to Kolodny, "changing hydrocodone-combination products from Schedule III to Schedule II may be the single most important federal intervention that could be taken to bring this epidemic under control."

Webster said he remained "seriously concerned about both of these issues [access and diversion]," but also felt that there were alternatives to reclassifying.

"We need more education about how to safely prescribe these drugs and identify people who are safe candidates and prescribe less," he said. "At the same time, we need a national campaign that informs the public and people who are receiving the medications that it's dangerous to have leftover medications and that they need to find ways to dispose of their medications or not accept a prescription."

More information

Visit the U.S. National Library of Medicine for more on prescription drug abuse.

SOURCES: Andrew Kolodny, M.D., president, Physicians for Responsible Opioid Prescribing, and chair, psychiatry, Maimonides Medical Center, New York City; Lynn Webster, M.D., president-elect, American Academy of Pain Medicine; U.S. Food and Drug Administration


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Panel Rejects Ovarian Cancer Screening
2. FDA Panel Gives Blessing to New Weight-Loss Drug
3. FDA Panel to Consider At-Home HIV Test
4. FDA Panel Backs At-Home HIV Test
5. Screen All Adults for Obesity: U.S. Panel
6. Few Patients Should Get Metal-on-Metal Hip Implants, FDA Panel Says
7. Expert Panel Suggests PSA Test May Benefit Some Men
8. Expert panel calls for new research approach to prevent youth violence
9. U.S. Panel Rejects Ovarian Cancer Screens for Low-Risk Women
10. CDC Panel: All Pregnant Women Should Get Whooping Cough Shot
11. FDA Panel Considers 1st Drug for Chronic Fatigue Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Votes for Tougher Curbs on Vicodin, Other Painkillers
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of ... (ALCA) to conduct a survey that takes a closer look at cases of TBI ... prevalence and causes of TBI among the aging population, and identifies the challenges associated ...
(Date:2/10/2016)... ... February 10, 2016 , ... Gout is like no other ... that is often severe, with intense swelling and redness. It is triggered by the ... but older adults are the most susceptible, according to the February 2016 issue of ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association for ... speaker Jan Fox will serve as keynote speaker at the organization’s 2016 Spring ... tools to more effectively communicate with their own organizational staff and leadership. ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... it will attend the Ohio Safety Congress and Expo event March 9-11, 2016. ... the Greater Columbus Convention Center. , As the longest running and largest ...
(Date:2/10/2016)... Middleboro, MA (PRWEB) , ... February 10, 2016 ... ... of their revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns ... to provide a solution that ensures the integrity of biological samples while operating ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Calif. , Feb. 10, 2016 /PRNewswire/ ... a synergistic confluence of various technologies that ... propositions, previously unavailable. These opportunities create a ... convergence, in turn, drives the development of ... scenario is characterized by technology convergences, which ...
(Date:2/10/2016)... PRINCETON, New Jersey and OR AKIVA, ... Regentis Biomaterials Ltd., a leader ... of its Series D investment round on February 5, ... Haisco Pharmaceutical Group ("Haisco"), a leading Chinese pharmaceutical ... Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and ...
(Date:2/10/2016)... DIEGO , Feb. 10, 2016 ALSP, Inc. ... , MD as Consultant for Medical Affairs in preparation for ... Michael Pierschbacher , PhD, CEO, stated, "We are pleased ... We look forward to working with an individual of such ... We look forward to drawing deeply on his broad experience ...
Breaking Medicine Technology: